Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach

Hyo Sung Jung, Jiyou Han, Hu Shi, Seyoung Koo, Hardev Singh, Hyo Jin Kim, Jonathan L. Sessler, Jin Yong Lee, Jong-Hoon Kim, Jong Seung Kim

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.

Original languageEnglish
Pages (from-to)7595-7602
Number of pages8
JournalJournal of the American Chemical Society
Volume139
Issue number22
DOIs
Publication statusPublished - 2017 Jun 7

Fingerprint

Carbonic anhydrase
Photodynamic therapy
Acetazolamide
Carbonic Anhydrases
Photochemotherapy
Tumors
Neoplasms
Photosensitizers
Chemical activation
Cells
Photosensitizing Agents
Angiogenesis Inducing Agents
Heterografts
Carbonic Anhydrase IX
Hypoxia

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Overcoming the Limits of Hypoxia in Photodynamic Therapy : A Carbonic Anhydrase IX-Targeted Approach. / Jung, Hyo Sung; Han, Jiyou; Shi, Hu; Koo, Seyoung; Singh, Hardev; Kim, Hyo Jin; Sessler, Jonathan L.; Lee, Jin Yong; Kim, Jong-Hoon; Kim, Jong Seung.

In: Journal of the American Chemical Society, Vol. 139, No. 22, 07.06.2017, p. 7595-7602.

Research output: Contribution to journalArticle

Jung, Hyo Sung ; Han, Jiyou ; Shi, Hu ; Koo, Seyoung ; Singh, Hardev ; Kim, Hyo Jin ; Sessler, Jonathan L. ; Lee, Jin Yong ; Kim, Jong-Hoon ; Kim, Jong Seung. / Overcoming the Limits of Hypoxia in Photodynamic Therapy : A Carbonic Anhydrase IX-Targeted Approach. In: Journal of the American Chemical Society. 2017 ; Vol. 139, No. 22. pp. 7595-7602.
@article{0cae20ae7146447cb8b9ff5870595cad,
title = "Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach",
abstract = "A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.",
author = "Jung, {Hyo Sung} and Jiyou Han and Hu Shi and Seyoung Koo and Hardev Singh and Kim, {Hyo Jin} and Sessler, {Jonathan L.} and Lee, {Jin Yong} and Jong-Hoon Kim and Kim, {Jong Seung}",
year = "2017",
month = "6",
day = "7",
doi = "10.1021/jacs.7b02396",
language = "English",
volume = "139",
pages = "7595--7602",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Overcoming the Limits of Hypoxia in Photodynamic Therapy

T2 - A Carbonic Anhydrase IX-Targeted Approach

AU - Jung, Hyo Sung

AU - Han, Jiyou

AU - Shi, Hu

AU - Koo, Seyoung

AU - Singh, Hardev

AU - Kim, Hyo Jin

AU - Sessler, Jonathan L.

AU - Lee, Jin Yong

AU - Kim, Jong-Hoon

AU - Kim, Jong Seung

PY - 2017/6/7

Y1 - 2017/6/7

N2 - A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.

AB - A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ)-conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photocytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.

UR - http://www.scopus.com/inward/record.url?scp=85020382009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020382009&partnerID=8YFLogxK

U2 - 10.1021/jacs.7b02396

DO - 10.1021/jacs.7b02396

M3 - Article

C2 - 28459562

AN - SCOPUS:85020382009

VL - 139

SP - 7595

EP - 7602

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 22

ER -